Stockwinners Market Radar for May 24, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Tharimmune Inc trading halted, news pending

17:36 EDT Adamas One receives noncompliance notification from Nasdaq - Adamas One reported that it has a hearing scheduled for May 30 before a Nasdaq Hearings Panel regarding its plan to regain compliance with Nasdaq Listing Rule 5550(a)(2); Nasdaq Listing Rule 5250; and Nasdaq Listing Rule 5250(c)(1). On May 20, the company received a letter from the Listing Qualifications Department of Nasdaq that, per the Filings Rule, the company is delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024, which serves as an additional basis for delisting the Company's securities from Nasdaq. The company intends to present a plan to regain compliance with the Minimum Bid Price Rule, the Fees Rule, and the Filings Rule, and request the continued listing of its common shares on Nasdaq pending such compliance.

17:25 EDT Oshkosh awarded $108.94M Army contract - Oshkosh was awarded a $108.94M firm-fixed-price contract for the Family of Medium Trucks. Bids were solicited via the internet with three received. Work locations and funding will be determined with each order, with an estimated completion date of September 30, 2026. Army Contracting Command is the contracting activity.

17:21 EDT Boeing awarded $7.48B Air Force contract - Boeing was awarded a $7.48B fixed-price-incentive-fee, firm-fixed-price, indefinite-delivery/indefinite-quantity contract action for Joint Direct Attack Munition, or JDAM. This contract provides for JDAM tail kits, spares, repairs, technical and Laser Joint Direct Attack Munition sensor kits. Work will be performed at St. Louis, Missouri, and is expected to be completed by February 29, 2030. This contract was a sole source acquisition. The Air Force Life Cycle Management Center is the contracting activity.

17:18 EDT Urban One receives second noncompliance notice from Nasdaq - Urban One reported that the company received a second letter from Nasdaq notifying the company that it was further non-compliant with Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Quarterly Report on Form 10-Q for the period ended March 31 with the SEC. The second Nasdaq notice noted that on April 8, Nasdaq sent the company a letter notifying the company that it was not in compliance with the Periodic Filing Rule as it did not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, with the SEC.

17:06 EDT Amplitude CFO Christopher Harms departs - Amplitude announced that Christopher Harms is no longer serving as the CFO and principal financial and accounting officer of Amplitude, effective immediately. Harms' departure from the company is not the result of any dispute or disagreement with the company's accounting principles or practices or financial statements and disclosures. The company has initiated a search for Harms' replacement.

17:03 EDT Ideanomics receives noncompliance notification from Nasdaq - Ideanomics announced that the company received a notice from Nasdaq stating that because the company has not yet filed its Form 10-Q for the period ended March 31, the company is not in compliance with Nasdaq Listing Rules for continued listing. The company is working diligently to regain compliance and will provide an update once more information is available.

17:01 EDT Destiny Tech100 reports Q1 NAV per share $5.07 vs $4.84 last quarter - Destiny Tech100 reported that its net asset value for the quarter ended March 31, 2024 totaled $5.07 per share of common stock, as compared to $4.84 per share as of December 31, 2023. As of March 31, 2024, Destiny Tech100 held positions in 23 portfolio companies - all privately held - for an aggregate fair value of approximately $51.7M, excluding short-term treasuries. The fund did not make investments in any new companies between January 1, 2024 and March 31, 2024.

16:33 EDT Li-Cycle board approves 8-for-1 share consolidation, names Dedo board chair - Li-Cycle Holdings updates from the Company's Annual General and Special Meeting of Shareholders held on May 23, 2024. Voting results of items of business at the AGM included the election of each of the Li-Cycle director nominees; the approval of the share consolidation resolution, described further below; the approval of the compensation of the Company's named executive officers on an advisory basis; the approval of a one-year frequency period for future advisory votes on the compensation of the Company's named executive officers on an advisory basis; and the approval of the adjournment of the AGM to permit Li-Cycle to complete the search for a successor independent auditor firm. Following approval by the Company's shareholders and its Board of Directors, the Company will effect a consolidation of the Company's common shares at a ratio of 8 pre-consolidation Shares for 1 post-consolidation Share. The Share Consolidation is expected to be effective before the markets open on June 4, 2024. Beginning on June 4, 2024, Li-Cycle's Shares are expected to begin trading on a post-consolidation basis on the New York Stock Exchange under the same symbol, "LICY," but under a new CUSIP number: 50202P204. The Share Consolidation is being implemented as a way to potentially increase the trading price of Shares so as to regain compliance with the closing share price criteria set forth in Rule 802.01C of the NYSE Manual. Under the terms of the Share Consolidation, every eight Shares will be automatically consolidated into one Share. The Share Consolidation will not change the authorized number of Shares. The Company would also like to announce the appointment of Jacqueline Dedo as Li-Cycle's independent Board Chair, effective immediately. Ms. Dedo succeeds Tim Johnston, Li-Cycle's previous interim non-executive Board Chair. As part of this transition, Mr. Johnston is also stepping down from the Li-Cycle Board, effective May 31, 2024, to pursue other business opportunities. Ms. Dedo will continue to serve as the Chair of the Board's Special Committee.

16:31 EDT Kuke to acquire majority stake in two Naxos One subsidiaries - Kuke Music Holdings Limited announced that on May 24, 2024, it has signed a non-binding term sheet with Naxos One Holding Limited, a limited liability company incorporated under the laws of the British Virgin Islands. The Term Sheet contemplates that Kuke will acquire a majority stake in two of the controlled subsidiaries of Naxos One, Angelina Assets Limited and HNH International Limited, the holding companies of the Naxos Music Group, a world-leading classical music brand and one of the largest distributors of independent classical record labels in the world. A director of Kuke is the controlling shareholder of Naxos One. The closing of the acquisition will be subject to entering into definitive agreements and the satisfaction of customary conditions, including Kuke's satisfaction with its due diligence regarding Naxos Group, and there is no assurance such transaction will be completed.

16:18 EDT Capital City Bank receives noncompliance notice from Nasdaq - Capital City Bank announced that it received a notice from Nasdaq stating that, as a result of not having timely filed its quarterly report on Form 10-Q for the quarter ended March 31, the company is no longer in compliance with the continued listing requirements of Nasdaq Listing Rule 5250, which requires listed companies to timely file all required periodic financial reports with the SEC.

16:11 EDT ToughBuilt receives noncompliance notice from Nasdaq - ToughBuilt announced that it has received a written notice from Nasdaq stating that because the company has not yet filed its Form 10-Q for the quarter ended March 31 and because the company remains delinquent in filing its Form 10-K for the year ended December 31, 2023, it is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the SEC.

16:03 EDT Inhibrx stockholder approve sale to Sanofi - Inhibrx (INBX) announced that, at a special meeting, the company's stockholders approved the sale to Sanofi (SNY) of all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency, or AATD. Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the company into a new publicly traded company, Inhibrx Biosciences. Subject to the terms of the definitive agreements announced on January 23, Sanofi will acquire all outstanding shares of Inhibrx through a merger with an indirect wholly owned subsidiary of Sanofi, and in turn, each Inhibrx stockholder as of the date of the closing of the Merger will receive: $30.00 per share in cash and one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone and (b) as of May 17, will rill receive one SEC-registered, publicly listed, share of New Inhibrx per every four shares of Inhibrx common stock held. In addition, in connection with the transactions, Sanofi will assume and retire Inhibrx's outstanding third party debt, and New Inhibrx will be funded with at least $200 million in cash, with Sanofi retaining an equity interest in New Inhibrx of 8% of outstanding shares of New Inhibrx common stock as of the date of the distribution of New Inhibrx shares. The company expects to announce consummation of the transactions within the coming days, subject to the satisfaction or waiver of certain customary closing conditions. Upon closing of the transactions, Inhibrx's common stock will be delisted from The Nasdaq Global Market and deregistered under the Securities Exchange Act of 1934, as amended and Inhibrx will no longer file periodic reports with the SEC on account of the company's common stock.

15:20 EDT Stericycle trading resumes

15:10 EDT Stericycle trading halted, volatility trading pause

14:01 EDT Redwoods Acquisition Corp trading resumes

13:41 EDT New Jersey Resources CEO Westhoven sells 20,000 common shares - In a regulatory filing, New Jersey Resources president and CEO Stephen Westhoven disclosed the sale of 20,000 common shares of the company on May 23 at a price of $42.8212 per share.

13:00 EDT Baker Hughes reports U.S. rig count down 4 to 600 rigs

12:40 EDT Netcapital announces intention to complete reverse stock split - Netcapital said it intends to file a proxy statement with the Securities and Exchange Commission on or about May 28, 2024 in connection with a special meeting of stockholders to be held on July 24, 2024. The proxy statement will include a proposal for a reverse stock split of its issued and outstanding shares of common stock at a ratio in the range of 1-for-2 to 1-for-100, with the exact range to be determined by the company's board of directors. The reverse stock split to be proposed to the company's stockholders in the proxy statement is intended to resolve the issue raised in notice the company received from the The Nasdaq Stock Market LLC on September 1, 2023 regarding the company's non-compliance with the minimum bid price requirement. The company can regain compliance at any time within the second compliance period if the closing bid price of the company's common stock is at least $1 for a minimum of ten consecutive business days.

12:22 EDT Cassava receives patent allowance for Alzheimer's disease assay - Shares of Cassava Sciences moved higher after the United States Patent and Trademark Office posted a patent allowance for an Alzheimer's disease assay in a living patient. The stock in midday trading is up 2% to $22.26.

12:04 EDT CI&T rises 17.0% - CI&T is up 17.0%, or 67c to $4.62.

12:02 EDT Dayforce falls -4.8% - Dayforce is down -4.8%, or -$2.89 to $57.91.

12:01 EDT Zeekr falls -5.3% - Zeekr is down -5.3%, or -$1.37 to $24.55.

11:37 EDT Ace Global Business Acquisition reports termination of merger agreement - Ace Global Business Acquisition Limited, a special purpose acquisition company, announced that the Business Combination Agreement dated December 23, 2022 between the company and LE Worldwide Limited, a British Virgin Islands business company, as supplemented by a Joinder Agreement dated March 2, 2023 between the Company, LE Worldwide, ACBA Merger Sub I Limited, a British Virgin Islands business company and wholly owned subsidiary of the Company, and ACBA Merger Sub II Limited, a British Virgin Islands business company and wholly owned subsidiary of Purchaser and as amended on July 6, 2023 and September 19, 2023, has been mutually terminated and that the Company is ceasing its business combination efforts. On May 24, 2024, the Company, Purchaser, Merger Sub and LE Worldwide entered into a Mutual Termination Agreement pursuant to which the Company, Purchaser, Merger Sub and LE Worldwide agreed to mutually terminate the Merger Agreement in all respects in accordance with Section 14.1(a) of the Merger Agreement. The Merger Agreement is effectively mutually terminated as of May 24, 2024. The parties' entry into the Mutual Termination Agreement was as a result of concern over LE Worldwide's ability to continue its operations post-business combination due to significant decline in its business revenue, liquidity issues with certain bank financings and uncertainty over the supply of the tools and products that it sells. On April 12, 2024, LE Worldwide's related party manufacturer and main supplier was served with a winding-up petition. Because the board of directors of the Company has determined that the Company may not have sufficient time to complete an initial business combination within the timeframe provided in the Company's current amended and restated memorandum and articles of association, the Company will therefore liquidate and dissolve in accordance with its terms. The Company will redeem all of its issued and outstanding ordinary shares that were included in the units issued in its initial public offering from its public shareholders and will work with its trustee to effect the liquidation in accordance with the terms of its Charter and as set forth in its prospectus issued in connection with the Company's initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless.

11:24 EDT Marathon Digital enters agreement with Ministry of Energy and Petroleum of Kenya - Marathon Digital Holdings has entered into an agreement with the Ministry of Energy and Petroleum of the Republic of Kenya to support the utilization of energy and to optimize renewable energy projects across the Republic of Kenya. The partnership underscores Marathon's commitment to supporting the sustainable growth of the energy sector and is part of the Company's broader strategy to diversify its operations globally. Under the terms of the agreement, MOEP and Marathon will exchange policy, scientific, and technical information, as well as project investment expertise, to better understand how to optimize renewable energy projects that produce surplus energy due to intermittency and seasonal variations. A Joint Steering Committee will be established that will be staffed by both MOEP and Marathon senior officials to ensure the development and implementation of these energy related projects across the country. With projected foreign investments expected to exceed $80 million, this venture is poised to deliver economic benefits to the Kenyan economy and generate revenue for the local energy sector ecosystem.

10:12 EDT Blue World Acquisition Corp trading halted, volatility trading pause

10:04 EDT Summit Therapeutics discloses ivonescimab data, sees TEAEs in 61.5% of patients - In a regulatory 8-K filing earlier this morning, the company stated: "On May 24, 2024, the National Medical Products Administration, the regulatory authority in China responsible for providing marketing authorization for clinical drug candidates, has approved ivonescimab in combination with chemotherapy for use in patients with epidermal growth factor receptor mutated, locally advanced or metastatic non-squamous non-small cell lung cancer, or NSCLC, who have progressed after treatment with an EGFR tyrosine kinase inhibitor. This is the first approval for ivonescimab by any regulatory authority. The approval for ivonescimab was based on the trial called HARMONi-A (AK112-301), a single region Phase III clinical trial conducted in China comparing ivonescimab plus chemotherapy vs. placebo plus chemotherapy in the aforementioned setting. The trial was sponsored by our partner, Akeso, Inc. (Akeso). Data for this trial was generated and analyzed by Akeso. This data is planned to be released at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting during an oral presentation on Friday, May 31, 2024, scheduled for 4:57pm CT. On May 23, 2024, ASCO released abstracts for presentations to take place during the Annual Meeting. Included in these abstracts, was topline data associated with HARMONi-A. Notably, patients receiving ivonescimab plus chemotherapy experienced a median progression free survival (PFS) by independent radiology review committee of 7.06 months (95% CI: 5.85 - 8.74) as compared to 4.80 months (95% CI: 4.21 - 5.55) for those patients receiving chemotherapy alone (hazard ratio: 0.46; 95% CI: 0.34 - 0.62). Grade 3 or higher treatment emergent adverse events, or TEAEs, occurred in 61.5% patients receiving ivonescimab plus chemotherapy as compared to 49.1% patients receiving chemotherapy; the most common grade of 3 of higher in TEAEs were chemotherapy related adverse events. Additional data and context including, but not limited to, response rates, stable disease rates, progression free survival, overall survival, and safety is expected to be made available during ASCO's Annual Meeting." Shares of Summit Therapeutics are down 24% at $3.28 on the disclosure of grade 3 or higher treatment emergent adverse events in in 61.5% patients.

10:03 EDT Yatsen falls -4.9% - Yatsen is down -4.9%, or -16c to $3.12.

10:02 EDT Azul rises 9.9% - Azul is up 9.9%, or 56c to $6.23.

10:00 EDT Deckers Outdoor rises 12.4% - Deckers Outdoor is up 12.4%, or $112.09 to $1016.74.

09:51 EDT Endava falls -4.0% - Endava is down -4.0%, or -$1.24 to $29.74.

09:49 EDT Azul rises 9.9% - Azul is up 9.9%, or 56c to $6.23.

09:47 EDT Deckers Outdoor rises 12.5% - Deckers Outdoor is up 12.5%, or $112.70 to $1017.35.

09:41 EDT Viavi terminates plan to acquire Spirent Communications - Viavi stated: "On 5 March 2024, the boards of Viavi Bidco and Spirent announced that they had reached agreement on the terms of a recommended cash offer by Viavi Bidco to acquire the entire issued and to be issued share capital of Spirent for an acquisition value of 175 pence per Spirent Share, comprising cash consideration of 172.5 pence and a permitted special dividend payment of 2.5 pence per Spirent Share. Such offer was to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act. On 27 March 2024, Spirent published the scheme document to convene the Court Meeting and General Meeting of Spirent Shareholders to approve the Viavi Scheme, with such meetings to be held on 1 May 2024. Defined terms used but not otherwise defined in this announcement have the meanings given to them in the Scheme Document. On 28 March 2024, the boards of Spirent and Keysight Technologies Inc. announced that they had reached agreement on the terms of a recommended cash offer by Keysight to acquire the entire issued and to be issued share capital of Spirent for an acquisition value of 201.5 pence per Spirent Share, comprising cash consideration of 199 pence and a permitted special dividend payment of 2.5 pence per Spirent Share. The announcement on 28 March 2024 included the withdrawal by the Spirent Directors of their recommendation of the Viavi Offer. On 17 April 2024, the Viavi Scheme Shareholder Meetings, due to be held on 1 May 2024, were adjourned indefinitely. The Viavi Scheme was conditional, amongst other things, on the Viavi Scheme Shareholder Meetings being held on or before the 22nd day after 1 May 2024, being the expected date of the Viavi Scheme Shareholder Meetings. Accordingly, conditions 2.1(b) and 2.2(b), as set out in Part III of the Scheme Document, have not been satisfied by 23 May 2024 and, as such, the Viavi Scheme has lapsed. In addition, Viavi Bidco has served notice to terminate the Co-operation Agreement." Reference Link

09:38 EDT Renovaro BioSciences, Amsterdam UMC Cancer Center announce intended partnership - Renovaro and the Amsterdam UMC Cancer Center announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy. Both Renovaro and Amsterdam UMC emphasize the need to carry out the appropriate corporate and scientific due diligence before taking these next steps. Alongside the independent validation any final contractual commitments are subject to approval from both executive boards.

09:37 EDT EnWave sells 100kW REV to BranchOut FoodsBranchOut Food - EnWave Corporation (NWVCF) announced that it has signed an equipment purchase agreement with BranchOut Foods Inc. (BOF). BranchOut requires additional Radiant Energy Vacuum, REV, drying capacity to meet the increasing demand for their premium, healthy fruit and vegetable products. This is the third large-scale REV machine purchased by BranchOut.

09:30 EDT Martin Midstream Partners receives $3.05 per share buyout offer from MRMC - Martin Midstream Partners announced that Martin Resource Management Corporation, or MRMC, filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission. The 13D Amendment discloses that MRMC has made a non-binding proposal to the Conflicts Committee of the board of directors of Martin Midstream, the general partner of MMLP, pursuant to which MRMC would acquire all of the outstanding Common Units of MMLP not already owned by MRMC or its subsidiaries for a cash purchase price of $3.05 per Common Unit. The other terms of proposal are set forth in the 13D Amendment. The proposed transaction is subject to several contingencies, including the approval of the Conflicts Committee and the GP Board, the approval by MMLP's unitholders, and the satisfaction of any conditions to the consummation of a transaction set forth in any definitive agreement concerning the transaction. There can be no assurance that definitive documentation will be executed or that any transaction will materialize on the terms described above or at all.

09:10 EDT SunPower reports COO Jennifer Johnston terminated - In a regulatory filing, SunPower disclosed that on May 21, the board of directors of SunPower Corporation terminated the employment of Jennifer Johnston, the Executive Vice President and Chief Operating Officer of the company, effective as of June 7.

09:08 EDT Adams Diversified Equity Fund announces initiatives to enhance shareholder value - Adams Diversified Equity Fund announced two initiatives reflecting our ongoing commitment to long-term shareholder value creation: the implementation of a managed distribution policy that will provide a higher annual distribution rate more evenly on a quarterly basis throughout the year and a tender offer expected to commence on July 5, 2024. These initiatives underscore our dedication to delivering long-term value, competitive performance, and stable, consistent distributions to our valued shareholders. Under the new Policy, the Fund commits to distribute a minimum 8% annual rate of the Fund's average net asset value to shareholders beginning with the third quarter distribution expected to be paid at the end of August 2024. The Fund expects to distribute 2% of average NAV for each quarterly distribution, with the fourth quarter distribution expected to be the greater of 2% of average NAV or the amount needed to satisfy minimum distribution requirements of the Internal Revenue Code for regulated investment companies. Average NAV will be based on the average of the previous four quarter-end NAVs per share prior to each declaration date. The distributions may consist of year-to-date estimated net investment income, capital gains, and/or return of capital, and will be payable in shares of common stock or optionally in cash by specific shareholder election. This Policy will provide regular, more predictable distributions and replaces the 6% minimum annual distribution commitment based on market value that the Fund had established and met since 2011. The Fund's distribution level will be monitored and may be changed in the future by the Board as warranted. In addition, the Fund will conduct a tender offer for 10% of its outstanding shares at a price of 98% of NAV per share. A tender offer provides liquidity at a predetermined price to shareholders seeking to rebalance their portfolios, without having to sell their shares on the open market. The tender offer period is expected to commence on July 5, 2024 and expire on August 2, 2024.

09:06 EDT Mullen Automotive announces GAMA as distribution partner for the Balkans - Mullen Automotive announces GAMA as an additional European distribution partner for southeastern Europe covering the Balkans Region, which includes Bosnia Herzegovina, Serbia, Montenegro, Croatia, Slovenia, Macedonia, Albania, Greece and Bulgaria. GAMA will represent Mullen's full commercial electric vehicle product line. GAMA has extensive experience with electric vehicles in the Balkan market and has distributed more than 300 vehicles in the last year including private and municipal sales. GAMA has a strong reputation responding to and winning public tenders for local government opportunities. GAMA's distribution network includes eight sub dealers in the Balkan Region supporting sales, service and parts operation and is currently building a new facility in Belgrade. GAMA's initial vehicle order includes 53 commercial EVs, consisting of urban delivery vehicles and commercial vans and trucks.

09:04 EDT Golden Star Acquisition cancels shareholder meeting for merger - Golden Star Acquisition announced that it has cancelled the extraordinary general meeting of its shareholders that was previously scheduled for May 30, 2024, and has withdrawn from consideration by the shareholders the proposals set forth in the Company's definitive proxy statement for the Business Combination EGM filed with the U.S. Securities and Exchange Commission on May 17, 2024. As previously announced, on September 16, 2023, the Company entered into a definitive business combination agreement with Gamehaus, a mobile game publishing company. On May 22, 2024, Gamehaus notified the Company that it received a written notice from the China Securities Regulatory Commission requiring it to complete the filing with the CSRC pursuant to the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies, as promulgated by the CSRC on February 17, 2023. Pursuant to Section 8.1 of the Business Combination Agreement, the obligations of the parties to consummate the transactions contemplated thereunder are subject to Gamehaus having received the necessary approval from the CSRC, among others. Therefore, the board of directors of the Company has decided to cancel the Business Combination EGM to allow more time for the closing conditions under the Business Combination Agreement to be met

08:58 EDT Verastem sinks after 27% response rate in ovarian cancer study - Verastem is stinking after the company provided an update on its RAMP 201 trial, saying 115 patients with recurrent low-grade serious ovarian cancer were treated with the combination of avutometinib and defactinib, of which 109 patients had measurable tumor masses at baseline and were eligible for formal efficacy evaluation as of the data cutoff. As of the data cutoff, all patients had a minimum follow-up of five months since enrollment. Confirmed objective response rates by blinded independent central review for patients evaluable for efficacy were 27% in all patients. Of the 32 patients who remained on study treatment at the data cutoff, 14 achieved a best response rate of stable disease or unconfirmed partial response and therefore have the potential to achieve a formal objective response upon further treatment. 60% of evaluable patients achieved either a complete response, partial response, or stable disease response for six months or longer. Shares of Verastem are down 59%, or $7.20, to $4.99 in premarket trading.

08:32 EDT Visionary Holdings announces ordinary share consolidation - Visionary Holdings announced that it intends to effect a share consolidation of its ordinary shares at a ratio of one post-split ordinary share for every fifteen pre-split ordinary shares so that every fifteen shares issued and outstanding will be combined into one share. Any fractional share of a shareholder resulting from the Share Consolidation will be rounded up to the nearest whole number of shares. The Share Consolidation will become effective at 12:01 a.m. EST on May 29, 2024. The company's ordinary shares will continue to be traded on the Nasdaq Capital Market under the symbol "GV" and will begin trading on a post-consolidation adjusted basis when the market opens on May 29, 2024. The CUSIP number for the company's ordinary shares following the Share Consolidation will be 92838F200.

08:23 EDT Children's Place sends letter to shareholders - In a letter to shareholders, Chairman of the Board Turki Saleh A. AlRajhi wrote, " The full transition of governance of The Children's Place was made on March 8, 2024. We took governance in the faith that we can protect and compound, at a reasonable rate of return, the per-share intrinsic value of TCP benefitting all fellow shareholders with whom I am aligned... Strategy Going Forward. We have no master plan. Master planning works perfectly in theory but more often fails in practice. We will always seek to be opportunistic, and the present board has enough skin-in-the-game and will take a more active role, not only in governance, but also in overseeing management's capital allocation decisions. While we have influence as board members, we cannot eliminate all poor decisions. Even if we execute really well, some things just take time. Without going into specifics, below are some preliminary observations on the strategy that we expect management to execute: Capital Allocation... Liquidity and Debt... Operational Efficiencies... Operating Controls... Compensation Structure and Decentralization... Culture... No Quarterly Calls and Market Guidance... Transparency and Open Communication... We seek to follow a tell-it-like-it-is policy, and we reckon, this is the best form of proper communication and is important, particularly when things do not go well, which is inevitable from time to time. We, like all candid boards and management, are not infallible."

08:15 EDT Azul, Gol Linhas announce codeshare agreement - Azul (AZUL) and GOL airlines (GOL) announce a commercial cooperation agreement that will connect their flight networks in Brazil through a codeshare agreement. This partnership covers all domestic routes operated exclusively, meaning rotes operated by one of the two companies but not the other. The agreement also encompasses frequent flyer programs, allowing Azul Fidelidade and Smiles members to earn points in their preferred program when purchasing segments included in the codeshare agreement. Consumers will benefit from this commercial partnership starting at the end of June, when the offer will become available through both companies' sales channels.

08:04 EDT BranchOut Food secures third EnWave dehydration machine - BranchOut Food (BOF) announced the expansion of its agreement with EnWave Corporation (NWVCF). As part of this enhanced partnership, BranchOut has purchased its third large-scale EnWave dehydration machine. This addition is strategically aimed at expanding its new facility in Peru, with operations anticipated to commence in Q3, ultimately completing an estimated $40M in production capacity with 40-50% estimated gross margins. The newly acquired 100kW NutraRev System, distinct from the two QuantaREV systems previously purchased, is designed to enhance throughput and improve margins, particularly in the B-to-B ingredient space. BranchOut currently operates a 60kW QuantaREV and has committed to a larger 120kW QuantaREV, both primarily aimed at branded and private label snackproducts. The addition of the NutraRev System is expected to bolster BranchOut's capabilities across different product lines. These machines will be instrumental in servicing BranchOut's significant orders, including approximately $8M from the nation's largest retailer, $1.1M from the nation's largest warehouse club, and other potential customers in the pipeline. This expansion will position BranchOut as one of the largest Radiant Energy Vacuum installations globally and the largest in Latin America. The strategic location in Peru, with its abundance of fresh produce and low-cost labor, further enhances BranchOut's competitive edge.

08:03 EDT Blue Bird reaches CBA with United Steelworkers union - Blue Bird announced that a collective bargaining agreement, or CBA, has been reached with the United Steelworkers, or USW. union. Eligible members of the USW voted overwhelmingly in favor of the three-year agreement. The CBA covers more than 1,500 production workers at Blue Bird's Fort Valley, Georgia facility.

08:02 EDT Mega Matrix: FlexTV forms strategic cooperation with TopReels - Mega Matrix announced that Yuder PTE, LTD, the company's indirect majority-controlled subsidiary and operator of FlexTV, has formed a strategic cooperation with Foxmedia Co., Ltd., 100% controlled subsidiary of Neorigin Co. and the operator of TopReels, the leading short drama platform in South Korea. The company and Neorigin Co. will jointly establish a $10M content fund aimed at promoting joint investments, production, and distribution of original short drama projects. MPU COO Steven Gao, FlexTV CEO Zhenjun Cao, NEORIGIN CFO Jimmy Liu, and TopReels head Ryan Jeong attended the signing ceremony. This collaboration signifies that FlexTV and TopReels will engage in an in-depth partnership in the Korean market to create and deliver high-quality original short drama content, thereby enhancing the quality of the short drama platform.

07:48 EDT Lucid Group to cut 6% of staff or about 400 employees - In a regulatory 8-k filing, the company stated: "On May 24, 2024, Lucid Group announced a restructuring plan intended to optimize the Company's operating expenses in response to evolving business needs and productivity improvements through a reduction of the Company's current employee workforce by approximately 400 employees, or approximately 6%. The Company expects to substantially complete the Plan by the end of the third quarter of 2024, subject to local law and consultation requirements. The Company estimates that it will incur a total of approximately $21 million to $25 million in charges in connection with the Plan, which consist primarily of charges related to severance payments, employee benefits, employee transition, and stock-based compensation. The Company expects that charges of approximately $19 million to $23 million will be recognized primarily in the second quarter of 2024, with the majority of such charges anticipated to be paid by the end of the third quarter of 2024. Substantially all of these charges are expected to result in cash expenditures. The charges related to stock-based compensation are not expected to be material."

07:36 EDT Verastem initiates rolling submission of avutometinib NDA - Verastem announced that it has initiated the rolling submission of a New Drug Applicatiol or NDA, to the FDA seeking accelerated approval of the combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, for adult patients with recurrent KRAS mutant low-grade serous ovarian cancer, who received at least one prior systemic therapy. The rolling review process allows the Company to submit completed sections of an application for review by the FDA before all sections become available. The initial sections of the application will include the nonclinical and quality sections. In discussions with the FDA, Verastem reached agreement to submit a primary efficacy analysis based on the RAMP 201 study with 12 months of follow up. Based on discussions with the FDA, we understand that the proposed indication for final submission of the clinical module can be expanded in the event Verastem provides data that demonstrates a substantial improvement over available therapy in the KRAS wild-type population. FDA has accepted Verastem's plan to submit the clinical module in the second half of 2024 to complete the NDA application. Previously, the FDA granted Breakthrough Therapy Designation for the combination for treatment of patients with recurrent LGSOC, regardless of KRAS status, following one or more previous lines of therapy and Orphan Drug Designation for the combination in certain LGSOC indications. The Company plans to request a priority review of the NDA. Currently, there are no FDA-approved treatments specifically for recurrent LGSOC.

07:32 EDT Ollie's Bargain Outlet wins bid to acquire eleven former 99 Cents Only Stores - Ollie's Bargain Outlet Holdings announced that at the conclusion of a final sale hearing, the United States Bankruptcy Court for the District of Delaware approved the Company's stalking horse bid to acquire eleven former 99 Cents Only Stores locations. The Company and debtor entered into an asset purchase agreement to acquire eleven former 99 Cents Only Stores locations for $14.6 million in cash. The locations were acquired through the auction process held in connection with 99 Cents Only Stores' bankruptcy proceedings. The bankruptcy court approved the sale of the eleven stores to the Company on May 23, 2024, with appropriate court orders to follow. Of the eleven store locations, three of these are owned properties and eight are leased properties with attractive rents and leasing structures, located in key markets across Texas. The acquisition is expected to close in early June.

07:31 EDT BridgeBio to present additional analyses from Phase 3 ATTRibute-CM study - BridgeBio Pharma announced that 12 oral and moderated poster presentations will be shared at the 2024 International Symposium on Amyloidosis, ISA, taking place in Rochester, Minnesota on May 26 - 30, 2024. BridgeBio will also host an investor call on May 29, 2024, at 5:30 pm ET to discuss the recent analyses and positive data from the ATTRibute-CM Phase 3 trial and emerging real-world evidence in ATTR-CM. The investor call will include presentations from Mathew Maurer, M.D. of Columbia University Irving Medical Center and Ahmad Masri, M.D., M.S. of Oregon Health & Science University.

07:02 EDT Bio-Path to present data at 2024 EHA Congress - Bio-Path Holdings announced an upcoming poster presentation at the 2024 European Hematology Association, EHA, Congress, taking place June 13-16, 2024 in Madrid, Spain. Jorge Cortes, M.D., Director of the Georgia Cancer Center, will present interim results from the Company's Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia. The data show prexigebersen continues to be well-tolerated and has now demonstrated compelling efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, both of which exceeded outcomes with frontline therapy.

07:02 EDT BioLineRx to present new data from CheMo4METPANC Phase 2 at ASCO - BioLineRx announced that an abstract including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial was accepted for presentation at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois. The CheMo4METPANC trial is evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard-of-care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer. Updated results of the pilot study portion of the Phase 2 study include a new analysis of paired pre- and on-treatment biopsy samples that demonstrated an increase in CD8+ T-cell density in tumors from all 11 patients treated with the combination of motixafortide, cemiplimab and standard-of-care chemotherapies gemcitabine and nab-paclitaxel. As of February 6, 2024, 7 patients achieved partial response (64%), including 6 confirmed partial responses, and 10 patients (91%) had disease control compared to historic partial response and disease control rates of 23% and 48%, respectively, with gemcitabine and nab-paclitaxel. Preliminary median progression-free survival was 9.6 months compared to historic median PFS of 5.5 months with gemcitabine and nab-paclitaxel.

07:01 EDT Questor Technology announces sale of clean combustion unit in Canada - Questor Technology has received a purchase order for $0.5 million dollars to supply a clean combustion unit to a large midstream company in Western Canada, an extension of an enduring relationship with over a million dollars of equipment sales in previous years, to effectively reduce site emissions. This ISO 14034 certified clean combustion unit safely handles acid gas, in addition to eliminating methane and other harmful pollutants at a 99.9 percent efficiency, exceeding stringent rules for emissions in Canada. Our innovative design significantly reduces capital, fuel, and operating costs for our clients at large gas processing facilities and refineries.

06:35 EDT LyondellBasell increases quareterly dividend 7% to $1.34 per share - LyondellBasell announced its board of directors has declared a quarterly dividend of $1.34 per share, representing a 7% increase over the company's first quarter dividend. The dividend will be paid to shareholders on June 10 with an ex-dividend and record date of June 3.

06:06 EDT Duckhorn Portfolio enters distribution agreements with RNDC, BBG - The Duckhorn Portfolio announced that it has entered into distribution agreements with Republic National Distributing Company and Breakthru Beverage Group. The company's entry into these agreements is the culmination of a comprehensive strategic evaluation of its wholesale distribution network across the United States, with the goal of driving the profitable growth of the company's sales through a substantial increase in focus and investment in the wholesale channel. It is expected that RNDC and BBG will begin distribution of Duckhorn's wines in their respective new territories during the summer.

06:02 EDT Organon, Shanghai Henlius Biotech: EMA validates MAAs for HLX14 - Shanghai Henlius Biotech and Organon announced that the European Medicines Agency has validated the marketing authorization applications for HLX14, an investigational Prolia and Xgeva biosimilar. Denosumab has been approved in various countries and regions under different trade names for a range of different indications such as for the treatment of osteoporosis in postmenopausal women at high risk for fracture, among others. In 2019, it was estimated that 32M Europeans ages 50 or above had osteoporosis, 25.5M of which were women.

05:18 EDT Azul, Gol Linhas announce codeshare agreement - Azul and Gol airlines announced a commercial cooperation agreement that will connect their flight networks in Brazil through a codeshare agreement. This partnership covers all domestic routes operated exclusively, meaning routes operated by one of the two companies but not the other. The agreement also encompasses frequent flyer programs, allowing Azul Fidelidade and Smiles members to earn points in their preferred program when purchasing segments included in the codeshare agreement. This agreement will bring enormous benefits to our customers. Both companies have a history of aviation development in Brazil, focused on customer service excellence. Consumers will benefit from this commercial partnership starting at the end of June, when the offer will become available through both companies' sales channels.

05:13 EDT The9 enters exclusive publishing license agreement with Wemade - The9 announced that its wholly-owned subsidiary China Crown Technology entered into an exclusive publishing license agreement with Wemade. Pursuant to the license agreement, China Crown will exclusively publish and service the new MIR M game in mainland China, in both Mobile and PC version. The game may include blockchain technology in accordance with relevant PRC laws and regulations, subject to further agreement between the parties. The license term is five years from the commercial launch date and may be extended for another one year if such extension is not objected by either Party. The commercial launch is expected in early 2025.